Your browser doesn't support javascript.
loading
First-in-human study of E7130 (a tumor microenvironment-ameliorating microtubule inhibitor) in patients with advanced solid tumors: Primary results of the dose-escalation part.
Doi, Toshihiko; Matsubara, Nobuaki; Naito, Yoichi; Kuboki, Yasutoshi; Harano, Kenichi; Ono, Makiko; Urasaki, Tetsuya; Ohmoto, Akihiro; Kawanai, Tsubasa; Hisai, Takashi; Ikezawa, Hiroki; Shiba, Sari; Ito, Ken; Semba, Taro; Asano, Osamu; Takahashi, Shunji.
Afiliação
  • Doi T; Department of Experimental Therapeutics, National Cancer Center Hospital East, Chiba, Japan.
  • Matsubara N; Department of Medical Oncology, National Cancer Center Hospital East, Chiba, Japan.
  • Naito Y; Department of Experimental Therapeutics, National Cancer Center Hospital East, Chiba, Japan.
  • Kuboki Y; Department of Medical Oncology, National Cancer Center Hospital East, Chiba, Japan.
  • Harano K; Department of General Internal Medicine, National Cancer Center Hospital East, Chiba, Japan.
  • Ono M; Department of Experimental Therapeutics, National Cancer Center Hospital East, Chiba, Japan.
  • Urasaki T; Department of Experimental Therapeutics, National Cancer Center Hospital East, Chiba, Japan.
  • Ohmoto A; Department of Medical Oncology, National Cancer Center Hospital East, Chiba, Japan.
  • Kawanai T; Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Hisai T; Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Ikezawa H; Department of Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
  • Shiba S; Japan and Asia Clinical Development Department, Oncology Business Group, Eisai Co., Ltd., Tokyo, Japan.
  • Ito K; Oncology Department, Medical Headquarters, Eisai Co., Ltd., Tokyo, Japan.
  • Semba T; Clinical Data Science Department, Medicine Development Center, Eisai Co., Ltd., Tokyo, Japan.
  • Asano O; Clinical Pharmacology Science Department, Medicine Development Center, Eisai Co., Ltd., Tokyo, Japan.
  • Takahashi S; Oncology Tsukuba Research Development, Discovery, Medicine Creation, Eisai Co., Ltd., Ibaraki, Japan.
Cancer ; 129(15): 2348-2359, 2023 08 01.
Article em En | MEDLINE | ID: mdl-37080942
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias / Antineoplásicos Limite: Humans Idioma: En Revista: Cancer Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Japão
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias / Antineoplásicos Limite: Humans Idioma: En Revista: Cancer Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Japão